Management strategies for isolated premature thelarche: a risk-stratified clinical pathway favoring "watchful waiting"

孤立性乳房早发育的管理策略:基于风险分层的临床路径,倾向于“观察等待”

阅读:2

Abstract

Isolated Premature Thelarche (PT) is a common clinical issue in pediatric endocrinology. Because its early presentation resembles that of Central Precocious Puberty (CPP), which requires intervention, its management is highly controversial, caught between "active intervention" and "watchful waiting." This leads to inconsistent clinical practices and significant anxiety for affected families. This review aims to move beyond this traditional dichotomy by conducting an in-depth analysis of the natural history, pathophysiological mechanisms, diagnostic criteria, and progression risks of PT. We propose a new paradigm for a tiered, individualized management approach based on risk stratification, providing a clear, evidence-based pathway for clinical decision-making. Through a comprehensive review of recent clinical studies, reviews, and expert consensus, this paper analyzes the theoretical basis and evidence supporting a "watchful waiting" strategy. It defines the rigorous initial evaluation and dynamic monitoring protocols required for its implementation and clarifies the quantitative indicators for transitioning from "observation" to "active intervention." For children with typical PT-characterized by a normal growth rate, no significant bone age advancement, a prepubertal pelvic ultrasound, and a very low basal luteinizing hormone level-"watchful waiting" or "active surveillance" is a safe, effective, and preferred management strategy. This is an active medical monitoring process, not passive waiting. "Active intervention" (i.e., Gonadotropin-Releasing Hormone agonist therapy) should be strictly limited to the few "progressive" cases that show sustained pubertal progression, growth acceleration, and significant bone age advancement during follow-up, and are confirmed as CPP by a Gonadotropin-Releasing Hormone stimulation test. The risk-stratified management pathway proposed herein aims to effectively address the clinical dilemma, avoid over-treatment, and achieve individualized, precise management for children with PT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。